Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Inclusion Criteria

• •Diagnosis of recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that has failed or progressed after at least 1 prior salvage chemotherapy regimen directed at recurrent/metastatic disease.
• •Measurable disease per disease specific RECIST version 1.1- patients with bone as their only site of disease will not be eligible
• •If history of brain metastases must be stable for at least 3 months after treatment - A brain CT scan will only be required in subjects with known brain metastases at the time of enrollment or in subjects with clinical signs or symptoms suggestive of brain metastases.
• •Available related HLA-haploidentical NK cell donor by at least Class I serologic typing at the A\&B locus
• •Age 18 years or older
• •GOG Performance Status ≥ 2 - refer to appendix III
• •Adequate organ function as determined by the following criteria within 14 days of the start of the preparative regimen, unless otherwise noted:
• •* Bone marrow: platelets ≥ 80,000 x 109/L and hemoglobin ≥ 9 g/dL, unsupported by transfusions; absolute neutrophil count (ANC) ≥ 1000 x 109/L, unsupported by G-CSF or granulocytes
• •* Renal function: estimated glomerular filtration rate (GFR) of ≥ 50 ml/min (based on the Fairview Laboratories formula at time of screening)
• •* Liver function: total bilirubin \< 1.5 times upper limit of institutional normal; AST, ALT, and alkaline phosphatase \< 3 times upper limit of institutional normal
• •* Cardiac: Left ventricular ejection fraction \> 40% (within 28 days of treatment start)
• •* Pulmonary function: \> 50% corrected DLCO and FEV1, if presence of pleural effusion due to metastatic disease \> 40% corrected DLCO and FEV1 is acceptable (within 28 days of treatment start)
• •Able to be off prednisone or other immunosuppressive medications other than that prescribed per protocol for at least 3 days prior to Day 0
• •At least 14 days must lapse between last prior anti-cancer treatment and 1st day of preparative regimen
• •Not pregnant or lactating - The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Participants of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy and agree to use adequate birth control during study treatment.
• •Able to tolerate intraperitoneal (IP) port placement and IP treatment administration in the opinion of the enrolling investigator
• •Voluntary written consent